• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Athersys Inc.

    9/19/22 3:52:15 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATHX alert in real time by email
    S-8 1 athx-20220919xs8.htm S-8 Document

    As filed with the Securities and Exchange Commission on September 19, 2022
    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    ATHERSYS, INC.
    (Exact name of registrant as specified in its charter)

    Delaware
    (State or other jurisdiction of
    incorporation or organization)
    20-4864095
    (I.R.S. Employer
    Identification No.)

    3201 Carnegie Avenue
    Cleveland, Ohio 44115-2634
    (Address of principal executive offices including zip code)
    Athersys, Inc. 2019 Equity and Incentive Compensation Plan
    (Full title of the plan)
    Mr. Daniel Camardo
    Chief Executive Officer
    Athersys, Inc.
    3201 Carnegie Avenue
    Cleveland, Ohio 44115-2634
    (216) 431-9900
    (Name, address, and telephone number, including area code, of agent for service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☐
    Accelerated filer
    ☐
    Non-accelerated filer
    ☒
    Smaller reporting company
    ☒
    Emerging growth company
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
    ☐



    1


    EXPLANATORY NOTE
    Athersys, Inc. (the “Registrant”) hereby files this Registration Statement on Form S-8 (the “Registration Statement”) to register an additional 840,000 shares of Common Stock, par value $0.001 per share (the “Common Stock”), under the Athersys, Inc. 2019 Equity and Incentive Compensation Plan (the “Plan”). The Plan is an amendment and restatement, effective July 28, 2022, as restated, of the Athersys, Inc. 2019 Equity and Incentive Compensation Plan, for which a previously filed registration statement on Form S-8 is effective. Pursuant to General Instruction E to Form S-8, this Registration Statement incorporates by reference the contents of the Registration Statement on Form S-8 (Registration No. 333-232075) filed by the Registrant on June 12, 2019, including all attachments and exhibits thereto, except to the extent supplemented, amended or superseded by the information set forth herein.

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 3. Incorporation of Documents by Reference.     
    The Registrant is subject to the informational and reporting requirements of Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”), and, in accordance therewith, files reports, proxy statements and other information with the Securities and Exchange Commission (the “Commission”). The following documents filed with the Commission by the Registrant are hereby incorporated by reference into this Registration Statement:

    (a)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (Commission File No. 001-33876), filed with the Commission on March 15, 2022;
    (b)The Registrant’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2022 and June 30, 2022 (Commission File No. 001-33876), filed with the Commission on May 6, 2022 and August 12, 2022, respectively;
    (c)The Registrant’s Current Reports on Form 8-K (Commission File No. 001-33876) filed with the Commission on January 21, 2022, February 11, 2022, March 24, 2022, April 28, 2022, May 12, 2022, June 2, 2022, June 9, 2022, June 21, 2022, July 8, 2022, August 2, 2022, August 4, 2022, August 17, 2022, August 29, 2022, September 12, 2022 and September 14, 2022; and
    (d)The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A (Commission File No. 001-33876) filed with the Commission on December 6, 2007 under the Exchange Act, as updated by Exhibit 4.1 to the Company’s Current Report on Form 8-K (Commission File No. 001-33876) filed on March 24, 2022, and all amendments and reports filed for the purpose of updating that description.

    All documents filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the effective date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold, will be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents.

    Any statement contained in any document incorporated or deemed to be incorporated by reference herein will be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded will not be deemed, except as modified or superseded, to constitute a part of this Registration Statement.



    2


    Item 8. Exhibits.
    Exhibit Number
    Description
    4.1
    Certificate of Incorporation of Athersys, Inc., as amended as of June 20, 2013 (incorporated herein by reference to Exhibit 3.1 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-33876) filed with the Commission on August 13, 2013)
    4.2
    Certificate of Amendment to Certificate of Incorporation of Athersys, Inc., as amended as of June 7, 2017 (incorporated herein by reference to Exhibit 3.1 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-33876) filed with the Commission on August 9, 2017)
    4.3
    Certificate of Amendment to Certificate of Incorporation of Athersys, Inc., as amended, effective as of June 16, 2021 (incorporated herein by reference to Exhibit 3.3 to the Registrant’s Registration Statement on Form S-3 (File No. 333-257409) filed with the Commission on June 25, 2021)
    4.4
    Certificate of Amendment to Certificate of Incorporation of Athersys, Inc., as amended, effective as of August 26, 2022 (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-33876) filed with the Commission on August 29, 2022)
    4.5
    Bylaws of Athersys, Inc., as amended and restated as of March 13, 2019 (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-33876) filed with the Commission on March 14, 2019)
    4.6
    Athersys, Inc. 2019 Equity and Incentive Compensation Plan (amended and restated effective July 28, 2022, as restated)*
    5.1
    Opinion of Jones Day*
    23.1
    Consent of Independent Registered Public Accounting Firm – Ernst & Young LLP*
    23.2
    Consent of Jones Day (included in Exhibit 5.1)*
    24.1
    Power of Attorney*
    107
    Calculation of Filing Fee Tables*

    *    Filed herewith



    3


    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cleveland, state of Ohio, on this 19th day of September 2022.

    ATHERSYS, INC.
    By: /s/ Daniel A. Camardo    
    Name: Daniel A. Camardo
    Title: Chief Executive Officer and Director
    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
    Date: September 19, 2022/s/ Daniel A. Camardo
    Daniel A. Camardo
    Chief Executive Officer and Director (Principal Executive Officer)
    Date: September 19, 2022*
    Kasey Rosado
    Interim Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
    Date: September 19, 2022*
    Ismail Kola
    Chairman
    Date: September 19, 2022*
    Kenneth Traub
    Director
    Date: September 19, 2022*
    Jane Wasman
    Director
    Date: September 19, 2022*
    Jack Wyszomierski
    Director
    ______________
    *
    This Registration Statement has been signed on behalf of the above officers and directors by Daniel A. Camardo, as attorney-in-fact, pursuant to a power of attorney filed as Exhibit 24.1 to this Registration Statement.
    Dated:September 19, 2022
    By: /s/ Daniel A. Camardo
    Daniel A. Camardo
    Attorney-in-Fact

    Get the next $ATHX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATHX

    DatePrice TargetRatingAnalyst
    11/19/2021$1.25Buy → Neutral
    B of A Securities
    11/19/2021Buy → Neutral
    BofA Securities
    More analyst ratings

    $ATHX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Athersys Reports Third Quarter 2023 Financial Results and Business Highlights

    Athersys, Inc. (OTC:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and Recent Corporate and Operational Highlights: Announced results of a blinded interim analysis of Phase 3 MASTERS-2 clinical trial studying MultiStem for treatment of ischemic stroke indicating additional patients would need to be added to the trial to achieve statistical significance with a primary endpoint of mRS Shift Analysis at Day 365. Completed warrant exercise inducement generating gross proceeds of $3.

    11/16/23 8:30:00 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

    Athersys, Inc. (NASDAQ:ATHX), ("Athersys" or the "Company") a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. ("Healios") under the acute respiratory distress syndrome ("ARDS") global license. On October 11, 2023, Athersys entered into a warrant exercise inducement offer letter (the "Inducement Letter") with a holder of certain existing warrants ("Holder") to receive new warrants

    10/16/23 4:52:00 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

    The MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestones Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company's ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients is insufficiently powered to achieve the primary endpoint of mRS Shift analysis at Day 365. There were no safety issues identified. Because the s

    10/10/23 8:30:00 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    SEC Filings

    View All

    Athersys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ATHERSYS, INC / NEW (0001368148) (Filer)

    1/8/24 7:31:19 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Athersys Inc.

    25-NSE - ATHERSYS, INC / NEW (0001368148) (Subject)

    12/27/23 9:01:00 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athersys Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update

    8-K - ATHERSYS, INC / NEW (0001368148) (Filer)

    12/22/23 5:09:11 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Hansen Maia covered exercise/tax liability with 67 shares, decreasing direct ownership by 0.10% to 70,010 units (SEC Form 4)

    4 - ATHERSYS, INC / NEW (0001368148) (Issuer)

    12/21/23 11:37:15 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hansen Maia covered exercise/tax liability with 23,149 shares, decreasing direct ownership by 25% to 70,144 units (SEC Form 4)

    4 - ATHERSYS, INC / NEW (0001368148) (Issuer)

    10/6/23 5:34:28 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Camardo Daniel A. covered exercise/tax liability with 19,993 shares, decreasing direct ownership by 7% to 285,341 units (SEC Form 4)

    4 - ATHERSYS, INC / NEW (0001368148) (Issuer)

    10/6/23 5:28:22 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Athersys downgraded by B of A Securities with a new price target

    B of A Securities downgraded Athersys from Buy to Neutral and set a new price target of $1.25

    11/19/21 8:21:00 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athersys downgraded by BofA Securities

    BofA Securities downgraded Athersys from Buy to Neutral

    11/19/21 7:12:53 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    Financials

    Live finance-specific insights

    View All

    Athersys to Host Business Update Conference Call on August 9th

    Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress and discuss timing to conduct an interim analysis with MASTERS-2, a Phase 3 pivotal trial of MultiStem treatment in ischemic stroke. Date

    7/31/23 1:38:00 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athersys to Host Business Update Conference Call on April 20th

    Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on April 20, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress and discuss upcoming milestones supporting the pivotal Phase 3 ischemic stroke trial, MASTERS-2. Date April 20, 2023 Time

    4/10/23 3:29:00 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athersys to Host Business Update Conference Call on February 14th

    Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert "Willie" Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress, upcoming milestones and vision for the year. Date February 14, 2023 Time 11:00 a.m. (Eastern Time) Live webcast re

    2/2/23 8:30:00 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    Leadership Updates

    Live Leadership Updates

    View All

    Athersys Appoints Neema Mayhugh, PhD to its Board of Directors

    Healthcare Executive and Strategy Consultant Brings Considerable Innovation, Commercialization and Entrepreneurial Expertise Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neema Mayhugh, PhD to its Board of Directors. Dr. Mayhugh is an executive with more than 20 years of experience in healthcare consulting, industry, academic and hospital settings. Dr. Mayhugh currently serves as the Founder and Managing Partner of Wave Strategy, a consultancy focused on the rapid commercialization of healthcare innovations. Under her leadership, Wave Strategy has bridged early-stage t

    8/11/23 8:00:00 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Murchinson Issues Letter to Fellow Shareholders Regarding the Urgent Need for Boardroom Change at Nano Dimension

    Believes the Stern-Controlled Board's Decision to Challenge Our Special Meeting Demand – Without Any Valid Justification – Reinforces the Need for Objective and Independent Perspectives in the Boardroom Contends the Company is Making Misleading Claims About Murchinson to Distract from Mr. Stern Having Presided Over a More Than 77% Share Price Decline Since Becoming Chairman Puts Forward Proposals to Remove Four Incumbents and Appoint Two Highly Qualified, Independent Director Candidates with Sorely Needed Capital Allocation Acumen and Corporate Governance Expertise Sees a Clear Opportunity to Optimize Nano Dimension's Overcapitalized Balance Sheet, Explore Strategic Options to Maximize V

    2/2/23 5:25:00 PM ET
    $ATHX
    $IMMR
    $NNDM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer peripheral equipment
    Technology

    Athersys Appoints Joseph Nolan to Its Board of Directors

    Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph "Joe" Nolan to its Board of Directors, effective January 4, 2023. Mr. Nolan is an experienced biotechnology and pharmaceutical executive who currently serves as Chief Executive Officer of Jaguar Gene Therapy, LLC. With this appointment, Athersys has five Directors, four of whom are independent. "Joe is a strong addition to our Board, bringing more than 30 years of experience managing high-value global pipelines, launching multiple successful drugs and optimizing large-scale commercial operations. His understanding of th

    1/5/23 4:33:00 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Athersys Inc.

    SC 13G - ATHERSYS, INC / NEW (0001368148) (Subject)

    7/8/22 4:57:01 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Athersys Inc. (Amendment)

    SC 13G/A - ATHERSYS, INC / NEW (0001368148) (Subject)

    2/9/22 3:24:54 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Athersys, Inc. (Amendment)

    SC 13D/A - ATHERSYS, INC / NEW (0001368148) (Subject)

    9/21/21 9:14:13 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care